Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists

US8236818B2 · kind B2 · utility

Assignee

• Santhera Pharmaceuticals (Schweitz) AG · CH

Inventors

• Günther Metz · Edingen-Neckarhausen, DE
• Holger Deppe · Heidelberg, DE
• Ulrich Abel · Schifferstadt, DE
• Achim Feurer · Wilhelmsfeld, DE
• Inge Ott · Ketsch, DE
• Sonja Nordhoff · Aachen, DE
• Michael Soeberdt · Bielefeld, DE
• Barbara Hoffmann-Enger · Therwil, CH
• Philipp Weyermann · Sissach, CH
• Hervé Siendt · Allschwil, CH
• Christian Rummey · Basel, CH
• Miroslav Terinek · Münchwilen, CH
• Marco Henneböhle · Rheinfelden (Baden), DE
• Holger Herzner · Tuttlingen, DE
• Cesare Mondadori · Berkeley Heights, US

Key dates

• Filing date: Mar 28, 2008
• Grant date: Aug 7, 2012
• Expiry date: Apr 13, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.